



24 **Abstract**

25           Many bacterial pathogens strictly rely on the activity of type III secretion systems (T3SSs)  
26 to secrete and translocate effector proteins in order to establish infection. The central component  
27 of T3SSs is the needle complex, a supramolecular machine which assembles a continuous conduit  
28 crossing the bacterial envelope and the host cell membrane to allow bacterial effectors to gain  
29 entry into the host cell cytoplasm to modulate signal transduction processes. Disruption of this  
30 process impairs pathogenicity, providing an avenue for antimicrobial design. However, the  
31 molecular principles underlying T3 secretion remain elusive. Here, we report the first structure of  
32 an active *Salmonella enterica* sv. Typhimurium needle complex engaged with the late effector  
33 protein SptP in two functional states, revealing the complete 800Å-long secretion conduit and  
34 unravelling the critical role of the export apparatus (EA) subcomplex in T3 secretion. Unfolded  
35 substrates enter the EA through a hydrophilic constriction formed by SpaQ proteins, which enables  
36 side chain-independent transport, explaining heterogeneity and structural disorder of signal  
37 sequences in T3SS effector proteins. Above, a methionine gasket formed by SpaP proteins  
38 functions as a gate that dilates to accommodate substrates but prevents leaky pore formation to  
39 maintain the physical boundaries of compartments separated by a biological membrane. Following  
40 gate penetration, a moveable SpaR loop first folds up to then act akin to a linear ratchet to steer  
41 substrates through the needle complex. Together, these findings establish the molecular basis for  
42 substrate translocation through T3SSs, improving our understanding of bacterial pathogenicity and  
43 motility of flagellated bacteria, and paves the way for the development of novel concepts  
44 combating bacterial infections.

45

46

47 **Main Text:**

48 Many important human pathogens including *Salmonella*, *Shigella*, *Yersinia*, and  
49 enteropathogenic *Escherichia coli* (EPEC) employ a conserved type III secretion system (T3SS)  
50 also termed injectisome to deliver a pleiotropic arsenal of proteins into target eukaryotic cells<sup>1</sup>.  
51 These proteins modulate host cell signal transduction processes to establish a biological niche  
52 within the host, making T3SSs crucial virulence determinants<sup>2</sup>. Yet, the precise mechanisms that  
53 allow these secretion systems to facilitate unfolded protein transport across the bacterial envelope  
54 and into the host cell while maintaining bacterial integrity remain poorly understood. Therefore,  
55 visualizing the translocation process at the molecular level is essential for our understanding of  
56 host-pathogen biology and the development of novel therapies targeting bacterial infection.

57 The T3SS is a large molecular machine, over 3.6 megadaltons in mass, spanning across the  
58 inner and outer bacterial membranes with an extracellular filamentous appendage extending out to  
59 target host cells. Chaperones present effector proteins in a non-globular, secretion-competent state  
60 to a cytoplasmic sorting platform complex, which sorts and loads effectors into the export  
61 apparatus (EA) subcomplex located inside the membrane-bound basal body<sup>3,4,5,6</sup>. Extending from  
62 the EA is a long, helical needle filament, capped by a tip complex that contacts the host cell  
63 membrane via assembly of a translocon pore<sup>7,8,9</sup>. The basal body and the needle filament,  
64 collectively termed the needle complex, function as a continuous conduit for effector protein  
65 translocation from the prokaryotic to the host cell cytoplasm<sup>10,11</sup>.

66 Accumulating structural information has revealed a shared common architecture between  
67 virulent and flagellar T3SSs, especially in the EA<sup>6,12-15</sup>. However, in all structures known to date,  
68 the proposed translocation channel through the EA is sealed by a gasket with an above loop,  
69 making comprehension of substrate transport through the needle complex difficult. Furthermore,

70 it remains unclear how the EA achieves selective effector protein transport given the multitude of  
71 proteins that are present in the bacterial cytoplasm.

72 Visualizing actively-secreting injectisomes is however difficult due to the rapid dynamics  
73 of protein transport. A pool of protein substrates is translocated through the T3SS in a hierarchical  
74 order upon host cell contact, although injectisomes can be artificially induced to secrete proteins  
75 *in vitro*<sup>4,16</sup>. It is unclear what proportion of these injectisomes actively secrete proteins as in  
76 *Salmonella*, induced cells can contain tens of needle complexes<sup>10</sup>. Furthermore, translocation is  
77 rapid, estimated at a rate of 7-60 molecules per second<sup>17</sup>. With this speed and temporal variability,  
78 isolated needle complexes likely lack protein substrates, or they dissociate during purification  
79 procedures. To overcome these hurdles, effector proteins can be artificially trapped in needle  
80 complexes by fusion to C-terminal tags resistant to unfolding<sup>18,19</sup>. We previously showed that the  
81 *Salmonella* late-translocated effector protein SptP fused to a GFP tag can be visualized as a  
82 subtracted density in the needle complex, confirming that the filament functions as the conduit for  
83 effector proteins<sup>18</sup>. However, direct visualization of a substrate throughout the complete secretion  
84 conduit has remained challenging, leaving the questions as to how and where the EA would  
85 eventually open to allow passage of effector proteins, while maintaining the integrity and  
86 composition of compartments separated by a biological membrane, unresolved.

## 87 **Results:**

88 To obtain molecular snapshots of a T3SS engaged with a substrate, we applied cryo-EM to  
89 purified injectisome complexes which had been enriched for trapped SptP3x-GFP by  
90 immunoprecipitation (Supplementary Figs. 1 and 2). Single particle reconstruction provided us  
91 with a non-symmetrized density map of the substrate-trapped needle complex in two active  
92 functional states, ranging from 2.4 to 4.5Å in resolution (Fig. 1, Supplementary Figs. 3-5,

93 Supplementary Table 1), and resolving a substrate density traversing through the complete  
94 secretion path from the cytoplasmic face of the needle complex to the extracellular filament (Fig.  
95 1a,b). The SptP density reveals that the effector protein adopts a non-globular fold during transport  
96 through the needle complex (Fig. 1). However, the positional and conformational flexibility of the  
97 substrate, propagated throughout the entire translocation path, impeded our efforts to assign  
98 specific residues. As a consequence, we modeled the SptP3x-GFP substrate as a polyalanine  
99 sequence (Supplementary Fig. 6).

100         Inside the needle complex, the substrate travels through a secretion conduit built by the  
101 EA, a decameric subcomplex made up of three proteins, SpaP (5x), SpaQ (4x), and SpaR (1x), the  
102 inner rod composed of PrgJ<sub>1-6</sub>, and the PrgI-containing filament (Figs. 1c and 2a). Together, these  
103 proteins form three discrete building blocks that are embedded within three oligomeric protein  
104 rings formed by InvG, PrgH and PrgK, a scaffold spanning the two bacterial membranes and the  
105 periplasm (Fig. 1a,b and Supplementary Fig. 7).

106         The EA can be further separated into three discrete sections which form a three-point  
107 pseudo-helical interface with the substrate that together consists of two hydrophilic constrictions  
108 containing conserved glutamine residues (hereafter referred to as Q1- and Q2-belt) that sandwich  
109 a hydrophobic methionine gasket (hereafter referred to as M-gate). The substrate enters the EA  
110 with its N-terminus through the portal containing the Q1-belt, continues through the M-gate and  
111 Q2-belt defining the EA channel, before reaching the atrium chamber of the inner rod and finally  
112 the filament tunnel (Fig. 2b).

113         To be able to investigate the structural changes underlying substrate transport, we also  
114 determined the structure of an apo-state complex. Focused refinement without any symmetry  
115 enforcement provided us with a reconstruction yielding an average resolution of  $\sim 3.3\text{\AA}$  and

116 resolving the entire EA, the inner rod and parts of the filament (Supplementary Fig. 8). The model  
117 that we built is in very good agreement with a published apo-state structure of the same complex  
118 (6pep) and structurally-related complexes (6r6b, 6r69, 6s3r, 6s3l, 6s3s), together showing (i)  
119 closed EAs share a conserved architecture with a defined 5:4:1 (SpaP:Q:R) stoichiometry and (ii)  
120 suggesting that a conserved mechanism orchestrates substrate translocation through these secretion  
121 systems (Supplementary Figs. 9 and 10)<sup>6,12,13</sup>. Intriguingly, our apo- and translocation-state EAs  
122 superimpose with a very low root mean square deviation (rmsd) of 0.49Å (SpaP:Q:R), revealing  
123 that in fact only subtle conformational changes are needed to facilitate substrate transport through  
124 the channel of the needle complex (Supplementary Fig. 11).

125         The substrate first engages the needle complex structure through the EA core complex  
126 portal formed by four SpaQ proteins, confirming our previous results that the central opening  
127 localizing to the cytoplasmic tip of the EA serves as the substrate entry site<sup>18</sup>. Four SpaQ loops  
128 connecting  $\alpha$ -helices  $\alpha 1$  and  $\alpha 2$  and a lone SpaR Gln208 together form the Q1-belt in the  
129 cytoplasmic tip of the EA core complex (Fig. 3a). SpaS, which binds to the EA complex and  
130 simultaneously wraps around all four SpaQ loops in the homologous and recombinantly produced  
131 EA structure from *Vibrio mimicus* (6s3l), dissociates from our substrate-engaged needle complex  
132 during purification, which could explain why SpaQ<sub>1</sub>, and to a lesser extent SpaQ<sub>2</sub>, adopt a more  
133 open conformation (rmsd: 1.27Å; Supplementary Fig. 12)<sup>13</sup>. SpaQ homologues of many important  
134 human pathogens share a conserved Gln-X-Gln-X-Gln motif within the aforementioned loop,  
135 which effectively renders the environment in the Q1-belt hydrophilic (Supplementary Fig. 13).  
136 The high sequence conservation strongly suggests that the Q1-belt plays an essential role for  
137 substrate translocation through bacterial T3SSs.

138           Based on the appearance of its density, the substrate is largely unfolded in the Q1-belt area  
139 of the translocation path, indicating sequences corresponding to loops and  $\beta$ -sheets in natively  
140 folded SptP have mostly been trapped in the EA portal (Figs. 2b and 3b, Supplementary Fig. 6).  
141 Notably, little structural information is available for the very N-termini of T3SS effector proteins,  
142 especially when complexed with their cognate chaperones, supporting prediction models in which  
143 these sequences are typically intrinsically disordered<sup>20,21</sup>. Therefore, it is conceivable that our  
144 model provides mechanistic insights into how substrate proteins are loaded into the needle  
145 complex. In total, the Q1-belt is shaped by thirteen glutamines (3x in each of the four SpaQs, 1x  
146 in SpaR) that localize within close proximity to the trapped SptP3x-GFP substrate. Out of these,  
147 Gln43 of SpaQ<sub>3</sub> and SpaQ<sub>4</sub> establish hydrogen-bond interactions with the substrate backbone  
148 carbonyl oxygens and amine hydrogens (Fig. 3b). Due to the spiral staircase arrangement, the  
149 SpaQ/R glutamines provide complementary interaction interfaces over a length of  $\sim 20\text{\AA}$ , which,  
150 upon successive binding to the substrate, cause an increase in avidity that stabilizes the substrate  
151 in the EA portal below the M-gate (Figs. 2 and 3b,c). Together, our structural data reveals that  
152 loading of effector proteins into the needle complex can be accomplished in a side chain-  
153 independent fashion and hence provides a rationale to explain the structural disorder and plasticity  
154 of N-terminal signal sequences observed in bacterial T3SS effector proteins.

155           Following engagement in the hydrophilic Q1-belt, the substrate asymmetrically twists up  
156 through the  $\sim 5.5\text{\AA}$ -wide M-gate (Fig. 4a,b). The loops between the fifth and sixth alpha helix of  
157 each of the five SpaP proteins contain three conserved methionine residues, which, together with  
158 conserved SpaR Phe212, form a hydrophobic constriction seen in substrate-free structures<sup>15,6,12,13</sup>  
159 (Fig. 4a,b and Supplementary Figs. 14-16). Similar to the Q1-belt, the pseudo helical structure of

160 the EA causes these methionines to form a  $\sim 20\text{\AA}$ -long, spiral staircase-like gate that shifts to  
161 accommodate the substrate passing through (Figs. 2 and 4a,b).

162 Notably, the SpaP pentamer (SpaP<sub>1-5</sub>) in our substrate-engaged structure superimposes well  
163 with its apo-state counterpart (rmsd:  $0.45\text{\AA}$ ), which reinforces the concept that transport of  
164 substrate proteins across the bacterial envelope does not involve large conformational changes but  
165 is facilitated by subtle rearrangements that, within the M-gate, are mostly limited to the side chains  
166 of the three methionines (Fig. 4a-b and Supplementary Fig. 11). Similar to the Q1-belt area, the  
167 density corresponding to the trapped substrate fits best to an unfolded polypeptide (Fig. 2b and  
168 Supplementary Fig. 6), which, together with the size constraints imposed by the M-gate ( $\sim 5.5\text{\AA}$ ),  
169 supports our observation that non-folded SptP sequences have been trapped in the EA.

170 To functionally characterize the M-gate based on our structural data, we reconstituted a  
171 *Salmonella* SpaP knockout strain (SpaP<sup>KO</sup>) with exogenous SpaP carrying mutations targeting the  
172 conserved methionine motif. Negative stain EM revealed that substitution of the motif with the  
173 aliphatic amino acids glycine and alanine (SpaP<sup>GGG</sup>, SpaP<sup>AAA</sup>), as well as cysteine (SpaP<sup>CCC</sup>),  
174 resulted in markedly reduced numbers of needle complexes under injectisome-inducing  
175 conditions, demonstrating that needle complex assembly is impaired in these strains (Fig. 4c and  
176 Supplementary Fig. 17). Because proteins forming the inner rod (PrgJ) and the filament (PrgI) are  
177 transported through the T3SS as a natural part of the injectisome assembly process, our data  
178 provides evidence that at least the alanine and cysteine mutant strains retain some ability to actively  
179 transport proteins through their mutated EAs and hence the methionine motif alone is not strictly  
180 required for substrate translocation<sup>22</sup>. However, all three strains display impaired growth kinetics,  
181 suggesting that the assembly of EAs whose M-gates are composed of residues with side chains  
182 smaller than methionine creates pores in the inner bacterial membrane that likely short circuit the



183 membrane potential and cause reduced pathogen fitness (Fig. 4d and Supplementary Figs. 18 and  
184 19). Consistent with this hypothesis, deletion of a single methionine has been shown to be  
185 sufficient to increase membrane conductance in the flagellar homologue FliP<sup>23</sup>.

186 To further corroborate this hypothesis, we introduced either tryptophans (SpaP<sup>WWW</sup>) or  
187 phenylalanines (SpaP<sup>FFF</sup>) into SpaP to mimic the hydrophobic properties of methionine. Evidently,  
188 substitution of the methionine motif with these amino acids did not affect bacterial growth kinetics  
189 (Fig. 4d and Supplementary Fig. 18). However, substitution with phenylalanine but not tryptophan  
190 restored needle complex assembly to almost wild-type levels, indicating that the bulky  
191 hydrophobic side chain of tryptophan effectively prevents leaky pore formation but, compared to  
192 methionine and phenylalanine, appears to be too inflexible to efficiently facilitate substrate  
193 translocation (Fig. 4c, Supplementary Fig. 17).

194 Based on our findings, we reasoned that substrates penetrating the methionine network of  
195 the EA cause an opening of what appears to be a hydrophobic gate just large enough to  
196 accommodate the unfolded substrate chain. By intimately engaging the translocating substrate, the  
197 M-gate effectively acts as a tight seal to facilitate transport but maintain the physical boundaries  
198 between the pathogen's cytoplasm and (i) its periplasm during needle complex assembly, (ii) the  
199 outside environment (prior to infection) and (iii) the host cell cytoplasm (during infection).

200 In the apo-state, a unique loop of residues 106-123 of SpaR extends horizontally out on top  
201 of the M-gate (Fig. 5a). Consistent with the recombinant export apparatus from *Shigella flexneri*  
202 injectisomes, SpaR residues Leu110 and Ile114 interface with the methionines of the M-gate  
203 below, creating what has been termed a 'plug' in the structurally-related flagellar system  
204 (Supplementary Fig. 20)<sup>12,15</sup>. In the map of our substrate-engaged complex, the SpaR loop or 'lid'  
205 adopts two distinct conformational states positioned vertically along the translocation path (Fig.

206 5a and Supplementary Fig. 21). In state 1, the predominant state in our substrate-trapped structure,  
207 the SpaR loop generates a narrow path,  $\sim 6\text{\AA}$  in width, to make way for the substrate on its passage  
208 to the more spacious atrium. Stabilized by the formation of an antiparallel  $\beta$ -sheet, the hydrophobic  
209 side chain of SpaR Ile114 is exposed towards the channel lumen where it directly faces the  
210 translocating substrate (Fig. 5a and Supplementary Fig. 21). In state 2, no secondary structure  
211 elements can be observed and SpaR Ile114 is rotated away from the channel, which increases the  
212 width of the translocation path from  $\sim 6\text{\AA}$  to approximately  $10\text{\AA}$  (Fig. 5a). PISA interface analysis  
213 revealed that neither of the two SpaR loop conformations forms stable interactions with residues  
214 building the translocation channel (state 1:  $\Delta G$ :  $-4.4$  kcal/mol,  $P = 0.86$ ; state 2:  $\Delta G$ :  $-4.1$  kcal/mol,  
215  $P = 0.85$ ), demonstrating that the SpaR loop is a moveable element that enjoys conformational  
216 flexibility during substrate transport (Fig. 5a and Supplementary Table 2).

217 The area surrounding the substrate on the height of the unfolded SpaR loop is shaped by a  
218 loop which connects  $\alpha$ -helices  $\alpha 2$  and  $\alpha 3$  in each of the five spirally-organized SpaP protomers  
219 (Fig. 5b). Reminiscent of the Q1-belt function, strictly conserved SpaP Gln44 and Gln45 localize  
220 within close proximity to the substrate, together generating an extended hydrogen-bonding  
221 donor/acceptor interface to engage with the backbone and polar side chains of the SptP substrate  
222 as it emerges from the M-gate and passes SpaR Ile114 (Fig. 5c and Supplementary Figs. 14 and  
223 15). Because of the striking similarity with the Q1-belt, we decided to name this region of the  
224 translocation path the Q2-belt.

225 Together, it appears conceivable that the mobile SpaR loop functions akin to a linear ratchet  
226 in which Ile114 represents the ‘pawl’, whose conformational changes are physically triggered by  
227 the side chains or ‘teeth’ of the translocating substrate to support its unidirectional movement  
228 towards the atrium. Noteworthy, in state 2 ( $\sim 10\text{\AA}$ ) but not state 1 ( $\sim 6\text{\AA}$ ) of the SpaR loop, the Q2-

229 belt provides sufficient space to also accommodate alpha helices, suggesting that the events that  
230 cause conformational switching of the SpaR loop may not be limited to unfolded substrates but  
231 may also be caused by translocating  $\alpha$ -helices, which may provide an additional explanation for  
232 the evident ambiguity of the substrate density in our map.

233 Besides its role as a translocon, the EA also functions as a structural scaffold onto which  
234 the inner rod protein PrgJ assembles (Figs. 1c and 2a). Six PrgJ protomers interface with 1+5  
235 SpaR+P proteins and previously unresolved lipids, together creating the atrium. This spacious  
236 chamber connects the channel, defined by the conical architecture of the EA, with the tunnel of  
237 the helical needle filament (Fig. 2). The novel lipids reside in a circular gap present in the upper  
238 EA, where they function to accommodate SpaP alpha helix  $\alpha$ 1 and stabilize the helical fork of  
239 PrgJ, together forming a nucleation seed that drives polymerization of the needle filament (Fig.  
240 6a). All PrgJ proteins cross the EA/InvG gap to engage into  $\beta$ -strand complementation interactions  
241 formed between their N-termini and  $\beta$ -sheet  $\beta$ 6 of the surrounding InvG subunits together  
242 stabilizing the inner rod within the confinement of the basal body (Supplementary Fig. 22).  
243 Notably, the lowest monomer PrgJ<sub>1</sub> has a unique fold which extends horizontally, interfacing the  
244 SpaR loop connecting  $\alpha$ -helices  $\alpha$ 2 and  $\alpha$ 3 before traversing SpaP<sub>1</sub> to then cross the gap between  
245 the EA and the basal body clarifying earlier reports in which this part could not be resolved and  
246 PrgJ<sub>2</sub> was speculated to interface in alternate locations (Supplementary Fig. 22)<sup>6</sup>. Likewise, also  
247 N-termini of previously unresolved PrgI<sub>1,4-5</sub> protomers cross the EA/InvG gap to interact with  
248 SpaP, PrgJ, and the basal body component InvG, with each of these PrgI N-termini forming unique,  
249 plastic interactions with its respective environment, providing a rationale as to why some  
250 mutations localizing to the PrgI N-terminus abrogate filament assembly *in cellulose* but not *in vitro*  
251 (Supplementary Fig. 23)<sup>24</sup>.

252 Further, the needle complex structure presented here provides a refined view on the helical  
253 PrgI filament which was built *de novo* into our non-symmetrized C1 map and hence, unlike in all  
254 other structures, no helical symmetry or restraints have been imposed. With an average axial  
255 helical rise of 4.41Å between subunits and a pitch of ~5.5 subunits, our C1 filament grows ~24.3Å  
256 per turn compared to ~23.8Å (6dwb), ~23.3Å (6ofh) and ~23.1Å (2lpz) in models obtained by  
257 helical reconstruction cryo-EM and NMR, respectively<sup>7,8,24</sup>. The quality of our map allowed us to  
258 model 72 PrgI subunits, covering a distance of ~36 nm and therefore our filament accumulates a  
259 total size difference of at least ~5.5Å. Despite this difference, the filament tunnel of our substrate-  
260 engaged structure adopts the form of a right-handed helix with a minimal inner diameter of ~13Å,  
261 which is indistinguishable from published apo-state structures and sufficiently large to  
262 accommodate  $\alpha$ -helices (Fig. 6b)<sup>7,8,14,24</sup>.

263 At the passage from the Q2-belt to the atrium, the density corresponding to the substrate  
264 diminishes, demonstrating that, in contrast to the three tight interfaces seen in the EA, the wider  
265 lumen in the atrium (~13.5Å versus ~5.5-10Å) provides the substrate with higher conformational  
266 flexibility (Fig. 2 and 6b,c and Supplementary Fig. 6). Interestingly, the substrate density reappears  
267 in the upper atrium from where it continues through the tunnel of the filament (Fig. 6c). Here, it  
268 assumes a tubular shape which, especially at higher map thresholds, is remarkably similar to those  
269 of  $\alpha$ -helices at low resolution, indicating that substrates that enter the secretion system potentially  
270 retain secondary structure elements or, alternatively, may partly refold during their passage  
271 through the filament (Fig. 6c).

## 272 **Discussion:**

273 Here, we report the first high-resolution snapshot of a type-III secretion system in an active,  
274 substrate-engaged conformation, providing insight into the molecular basis of protein transport

275 across the bacterial envelope, a process that is fundamental to the virulence of many pathogenic  
276 bacteria and the motility of all flagellated bacteria. Our substrate-engaged structure reveals the  
277 complete secretion channel through the EA core complex, confirming its role as an entry portal to  
278 the needle complex.

279 Surprisingly, the EA lumen exhibits most of the conformational changes seen in the  
280 substrate-engaged structure, an unexpected finding given the sheer size and complexity of the  
281 needle complex machine. This agrees with, albeit at lower resolutions, our earlier structure and  
282 with visualizations of *in situ* needle complexes contacting host cells, together suggesting that the  
283 needle complex forms a largely static channel, in contrast to other more dynamic secretion  
284 machines<sup>18,9,25</sup>. In fact, many residues involved in substrate translocation localize to loop regions,  
285 which together with low rmsd values between apo-state and substrate-engaged structures, supports  
286 the concept that the basal body rings and the bulk of the SpaPQR complex provide a scaffold to  
287 position critical residues in the secretion channel. It appears plausible that this rigid architecture is  
288 a necessity to traverse the bacterial envelope, to provide a stable docking base for the dynamic  
289 components of the cytoplasmic sorting platform and simply to withstand the forces two moving  
290 cells but also the translocation process itself exert on the secretion system<sup>4,26,27</sup>.

291 In line with this concept, all six PrgJ proteins of the inner rod and PrgI<sub>2,4</sub> of the filament  
292 base engage into interactions with the surrounding InvG proteins, together stabilizing the  
293 translocation conduit within the confinement of the basal body. To connect the conical shape of  
294 the EA with the helical filament, the inner rod protein PrgJ assumes a fold of a helical fork that is  
295 similar to those of the filament protein PrgI (Supplementary Figs. 22 and 23). Consequently, lipids  
296 that we find determine the shape of PrgJ, and hence the entire rod, are vital to its function as a  
297 nucleation seed that facilitates needle polymerization.

298 Strikingly, our substrate-trapped structure confirms the essential role of the EA core  
299 complex in T3 secretion, forming a conserved three-point interface with the substrate. The EA  
300 channel contains two hydrophilic Q-belts sandwiching the hydrophobic M-gate and movable SpaR  
301 lid, which together function as a gate and guide, to engage and steer substrates to the filament. By  
302 establishing complementary hydrophilic interactions with the substrate backbone, conserved  
303 glutamines facilitate effector protein translocation in a side chain-independent manner, an  
304 intriguing possibility due to the variety of different substrates accepted by T3SSs, which has also  
305 been exploited biotechnologically for secretion of artificially designed substrates (e.g. nanobodies,  
306 DARPins, monobodies, spider silk monomers, and viral epitopes)<sup>28-30</sup>.

307 Our data confirms the M-gate forms the main constriction in apo-state structures that shifts  
308 just enough to allow substrate passage. Evidently, this gate functions in flagellar systems as a seal  
309 to prevent unwanted leakage of metabolites and mutations increasing the gate size in our system  
310 impede cellular growth and T3SS secretion, which we believe is a result of creating leaky pores in  
311 the inner membrane, that likely impede the proton-motive-force (PMF) believed to power T3SS  
312 secretion<sup>23,31</sup>.

313 The unprecedented resolution achieved here enabled us to decipher a conformational  
314 switch of the SpaR lid which first folds up to make way for the translocating substrate to then  
315 function akin to a linear ratchet to facilitate continuous unidirectional motion of the unfolded  
316 substrate towards the filament. In closed states, the conformation of the SpaR loop can be traced  
317 only with sufficiently smoothed maps and at high map thresholds in both: isolated needle  
318 complexes (our structure & 6pep) and in the recombinant EA from *S. flexneri* (6r6b), suggesting  
319 that SpaR Leu110 and Ile114 are only weakly associated with the M-gate located below<sup>6,12</sup>.  
320 Interestingly, the flagellar homologue FliR typically utilizes two conserved phenylalanines, which

321 tightly pack into the hydrophobic methionine network, a structural adaptation likely necessary to  
322 withstand the centrifugal force caused by the rotating flagellum and hence to maintain bacterial  
323 integrity (Supplementary Fig. 16)<sup>15,12,13</sup>.

324 Our substrate-engaged structure reveals continuous density throughout the needle complex  
325 conduit, corresponding to mostly non-folded SptP3x-GFP sequences in the EA channel. In fact,  
326 the N-termini of many substrates are heterogenous in sequence and predicted to be intrinsically  
327 disordered over a length of ~15-35 residues and therefore are sufficiently long to consecutively  
328 penetrate through all three constrictions, which we envision could be the most important unifying  
329 feature of T3SS signal sequences<sup>20</sup>. In favor of this concept, chaperones rather than N-terminal  
330 signal sequences were found to be crucial for routing effector proteins to the injectisome sorting  
331 platform<sup>4</sup>. Conceivably, it appears tempting to assume that effector proteins experience a selection  
332 pressure that drives the evolution of their N-termini towards non-folding sequences to facilitate  
333 their loading into the needle complex and hence ensure secretion.

334 However, SicP chaperone proteins maintain the chaperone-binding domain of SptP in a  
335 non-globular state containing  $\alpha$ -helices, which raises the intriguing question whether or not further  
336 unfolding prior to entry into the secretion system is required<sup>3</sup>. Evidently, for  $\alpha$ -helices to be directly  
337 translocated through the EA channel, the narrow, ~5.5Å-wide lumen of the M-gate would have to  
338 open further (Fig. 6b,c). While we cannot rule out that  $\alpha$ -helices are in fact directly translocated  
339 through the EA, the tubular appearance of the density corresponding to the substrate in the filament  
340 in our map suggests that  $\alpha$ -helices may fold during their passage through the needle complex.  
341 Either way, the transport of  $\alpha$ -helices is likely advantageous, accelerating the folding of effector  
342 proteins upon arrival in the host cell cytoplasm and allowing them to elicit their effector functions  
343 faster, a process that would benefit pathogen fitness. Also, helical filament assembly could be more

344 effectively achieved by docking of the readily formed helices into their cognate interfaces at the  
345 distal end of the growing filament.

346 Future studies will also have to address the question whether the constrictions inside the  
347 EA channel are passive components that only change their conformation as a consequence of the  
348 penetrating substrate or, alternatively, are regulated by active gating mechanisms. Given that  
349 hardly any conformational differences are seen in the scaffolding parts of the SpaPQR proteins  
350 (Supplementary Fig. 9), it is difficult to imagine a cytoplasmic signal translating up to the M-gate  
351 or SpaR ‘lid’ prior to substrate engagement, instead suggesting that these structural elements shift  
352 in response to the substrate physically travelling through the channel. However, we cannot rule  
353 out the possibility that gating of the EA portal occurs through SpaS, which is mostly absent in our  
354 complexes but likely orchestrates the shape of the SpaQ loops building the Q1-belt in native  
355 injectisomes. Alternatively, SpaS could represent a physical link providing guidance for the  
356 approaching disordered N-terminus to help finding its way into the narrow cytoplasmic opening  
357 of the EA portal.

358 Based on the structure and biochemical work presented here, we propose a model of  
359 substrate secretion through the T3SS export apparatus (Fig. 7). 1) After chaperone removal and  
360 substrate unfolding by the ATPase, the substrate is guided to the EA portal engaging with the Q1-  
361 belt which accommodates effector proteins independent from their sequence. 2) The substrate  
362 transports up through the methionine network, disrupting its hydrophobic interface causing the  
363 methionines to shift apart and opens the M-gate. 3) The SpaR loop, resting above the M-gate and  
364 blocking the channel, extends upwards, assuming an open conformation, which together with the  
365 surrounding Q2-belt creates an interface to engage the substrate. 4) The unfolded SpaR loop  
366 contacts the passing substrate, functioning similar to a linear ratchet to prevent a back slipping of



367 the substrate and together with the Q2 belt guides the substrate up through the atrium and into the  
368 lumen of the filament.

## 369 **Methods**

### 370 Bacterial strains and plasmids

371 Experiments were conducted using a *S. enterica* sv. Typhimurium non-flagellated strain  
372 SB905 carrying the T3SS transcriptional regulator gene *hilA* expressed on the pSB3291 plasmid  
373 using an araBAD promoter as previously described<sup>18</sup>. The SptP-based substrate and the SptP  
374 chaperone sicP, were both expressed using a pACYCDuet-1 CmR plasmid (Merck Chemicals).  
375 The substrate construct consists of an N-terminal signal sequence, a SicP-chaperone-binding  
376 domain, three SptP effector domain repeats fused to eGFP and a 3× FLAG tag<sup>18</sup>.

### 377 Bacterial Growth Assay

378 Overnight cultures of *Salmonella* SB905 SpaP knockout strains complemented with either  
379 WT SpaP or with GGG, AAA, CCC, WWW, and FFF substitutions were grown with or without  
380 0.3 M NaCl supplementation (injectisome inducing vs non inducing conditions) under antibiotic  
381 selection. The following morning, cultures were normalized to an OD<sub>600</sub> of 0.5 before diluting 1:10  
382 in either non-inducing LB, or inducing media, LB supplemented with 0.3 M NaCl and 0.012% w/v  
383 arabinose, for injectisome assembly. Cultures were sampled at 1 hour intervals and OD<sub>600</sub>  
384 measurements were recorded using a spectrophotometer to calculate growth curves. Three  
385 independent experiments of three biological replicates were used for each strain and condition.  
386 Data and statistical analyses were visualized using the GraphPad Prism8 software package.

### 387 Needle Complex Counting

388 Overnight cultures of *Salmonella* SB905 SpaP knockout strains complemented with either  
389 WT SpaP or with M-gate substitutions were grown with 0.3 M NaCl supplementation under

390 antibiotic selection. The following morning, cultures were diluted 1:10 in injectisome-inducing  
391 media, LB supplemented with 0.3 M NaCl, 0.012% w/v arabinose and without antibiotics. After 5  
392 hours of growth, cultures were diluted to an OD<sub>600</sub> of 1.0 and 1 ml was collected and centrifuged  
393 for 5 min at RT, approx. 16000 x g. The pellets were resuspended in approximately 30 µl of LB  
394 and incubated at RT for 5 min. 1 ml of ice-cold water was mixed with the cells which were then  
395 incubated on ice for 5 min. 1.5 µl of DNase (Thermo Fisher Scientific) was added along with 20  
396 µl of 1 M MgCl<sub>2</sub> and incubated at RT for 10 min. 40 µl of 0.5 M EDTA and 150 µl of 1 M Tris-  
397 Cl (pH 7.5) were added and the cells were centrifuged for 30 min at 4°C, approx. 16000 x g. Pellets  
398 were resuspended with 1 ml of ice cold TE buffer and centrifuged again. Pellets were then  
399 resuspended in 10-50 µl of ice cold TE buffer and incubated at 4°C for approximately 20 min  
400 while shaking. Cells were applied to TEM grids and stained (see below) before imaging with a  
401 Thermo Fisher Talos L120C TEM. Twenty cells were imaged at varying magnifications and  
402 needle complexes were counted by three colleagues, independently. Counts from each person for  
403 each cell were averaged and the data was visualized using the GraphPad Prism8 software package.

#### 404 Purification of needle complexes

405 Needle complexes were purified either from *Salmonella* SB905 WT or SpaP KO strains as  
406 described previously<sup>5,18</sup>. Briefly, day cultures were grown for 5 hours in LB media supplemented  
407 with 0.3 M NaCl, 0.012% w/v arabinose and without antibiotics prior to harvesting. Needle  
408 complexes were extracted from the membranes using 0.4% w/v LDAO, and separated by CsCl  
409 centrifugation. Fractions containing assembled needle complexes were concentrated and used for  
410 negative staining or cryoEM. For purification of substrate-trapped complexes, SB905 expressing  
411 hilA and the substrate SptP3x-GFP with chaperone sicP was grown for 4 hours with an additional  
412 2 hour induction period using 1 mM IPTG prior to harvesting. To enrich for substrate-trapped

413 complexes, CsCl fractions containing needle complexes and the substrate were pooled and  
414 incubated with Anti-FLAG M2 magnetic beads (M8823, Sigma Aldrich/Merck KGaA) prewashed  
415 in FR3 buffer (10 mM Tris-HCl, pH 8.0, 0.5 M NaCl, 5 mM EDTA, 0.1% w/v LDAO) for 2.5  
416 hours under gentle agitation at 4°C. The beads were subsequently washed 12 times with FR3 buffer  
417 for 10 min each. Beads were eluted with FR3 buffer twice as mock elutions and subsequently  
418 eluted twice for 45 min with 2 mg/ml 3xFLAG peptide in FR3 buffer. These elutions were then  
419 pooled and pelleted in a Beckman TLA-110 rotor at 90k rpm for 35 min. T3SS pellets were  
420 resuspended for at least 1 hour in FR3 buffer under agitation at 4°C before TEM imaging.

#### 421 Negative staining TEM

422 4 µl of diluted sample was applied to carbon-coated copper grids and incubated for 40  
423 seconds. Grids were glow discharged before for 30 seconds at 25 mA using a GloQube® Plus  
424 Glow Discharge System (Electron Microscopy Sciences). The sample was blotted off, and the grid  
425 was washed briefly with 4 µl of staining solution (2% w/v PTA, adjusted to pH 7.0 with NaOH)  
426 and then stained with 4 µl of the staining solution for 20 sec. The stain was blotted off and the  
427 grids were air-dried for at least 1 min. Grids were imaged using a Thermo Fisher Scientific Talos  
428 L120C TEM with a 4K Ceta CEMOS camera.

#### 429 SPA cryoEM sample preparation and data collection

430 Purified apo-state needle complexes were applied to Quantifoil grids with either an  
431 additional layer of amorphous carbon (<1.6nm thick) or graphene oxide. Purified, substrate-  
432 trapped needle complexes were applied to Quantifoil grids floated with an approx. 1.1 nm layer of  
433 amorphous carbon on top. 4 µl of sample was applied onto glow-discharged grids (30 sec, 25 mA)  
434 and allowed to disperse for 0.5-2 min. The grids were blotted for 4-7 sec set at 100% humidity and  
435 plunge frozen in a liquid propane/ethane mixture cooled to liquid nitrogen temperatures, using a

436 Thermo Fisher Scientific Vitrobot Mark V. Vitrified samples were imaged on a Thermo Fisher  
437 Scientific Titan Krios TEM operating at 300 kV and equipped with a field emission gun (XFEG)  
438 and a Gatan Bioquantum energy filter. Movies consisting of 25 (apo) or 50 (substrate-trapped)  
439 frames, were automatically recorded using Thermo Fisher Scientific EPU software and a Gatan  
440 K2 or K3 camera, at 0.3 – 5.2  $\mu\text{m}$  defocus in counting mode (Supplementary Table 1).

#### 441 SPA image processing

442 SPA was performed using Relion 3.0 for the apo state needle complex and Relion 3.1-beta  
443 for the substrate-trapped needle complex<sup>32,33</sup>. Movies were motion-corrected<sup>34</sup>, dose-weighted and  
444 the CTF was determined using CTFFIND4<sup>35</sup>. Particles were automatically picked from the motion-  
445 corrected micrographs using crYOLO<sup>36</sup> trained with a subset of manually picked particles.  
446 Particles were extracted and binned for several rounds of 2D classification. A cleaned and  
447 unbinned data set was obtained by re-extraction and aligned to a rotationally averaged structure.  
448 Focused refinements with and without applying symmetry were performed to the individual sub-  
449 structures using respective 3D masks. After converged refinements, per particle CTF and Bayesian  
450 polishing was used to generate a new data set for another round of focused refinements. Final  
451 rounds of refinement were performed without any masking of particles. Overall gold-standard  
452 resolution (Fourier shell correlation (FSC) = 0.143) and local resolution as well as sharpened maps  
453 (B-factor: -30) were calculated with Relion 3.1-beta<sup>32</sup>.

#### 454 Model building, refinement and validation

##### 455 Apo state:

456 Model building into the T3SS apo-state map started by placing homology models for SpaP,  
457 SpaQ and SpaR, which were generated with SWISS-MODEL using *Vibrio mimicus* FliP, FliQ and  
458 FliR structures as templates (6s3l); PrgJ was modelled using Phyre2<sup>13,37,38</sup>. Together with PrgI

459 (2lpz), homology models for SpaP, SpaQ, SpaR and PrgJ were first fitted into the EM map using  
460 the fit-in-map tool in UCSF Chimera (v1.14) and then manually extended with Coot (v0.9-  
461 beta)<sup>7,39,40</sup>. A first refinement was performed with Rosetta controlled via StarMap (manuscript in  
462 preparation), followed by interactive refinement against the map density with ISOLDE (v.1.0b5),  
463 a molecular dynamics-guided structure refinement tool within ChimeraX (v.0.93)<sup>41,42</sup>. The  
464 resulting coordinate file was further refined with Phenix.real\_space\_refine (v.1.18-6831) using  
465 reference model restraints, strict rotamer matching and disabled grid search. Model validation was  
466 carried out using MolProbity server and EMRinger within the Phenix software package  
467 (Supplementary Table 1)<sup>43-46</sup>.

#### 468 Substrate-trapped state:

469 Existing models of PrgH (3gr1), PrgK (3gr5), InvG (4g08, G34-I173: lower OR), SpaP,  
470 SpaR, SpaS, PrgJ and PrgI were rigid body-fitted into the electron density map using the fit-in-  
471 map tool in UCSF Chimera (v1.14), followed by manual rebuilding in Coot (v0.9-beta)<sup>39,40,47,48</sup>.  
472 The upper OR (InvG: E174-G557) was first built into a C15-symmetrized and focus-refined map  
473 using Coot (v0.9-beta) for *ab-initio* model building, followed by rigid body-fitting into the C1  
474 density map using the fit-in-map tool in UCSF Chimera v1.14<sup>39,40</sup>. Interactive refinement against  
475 the C1 map density was performed with ISOLDE (v.1.0b5)<sup>41</sup>. The resulting coordinate file was  
476 further refined with Phenix.real\_space\_refine (v.1.18-6831) using reference model restraints, strict  
477 rotamer matching and disabled grid search<sup>45</sup>. Model validation was carried out using MolProbity  
478 server and EMRinger (Supplementary Table 1)<sup>43,44,46</sup>. The translocation channel through the export  
479 apparatus and lumen of the needle filament was calculated using HOLE<sup>49</sup>. The helical rise of the  
480 PrgI filaments from the substrate-trapped filament, 2lpz, 6ofh, and 6dwb were measured by  
481 running the Rosetta tool `make_symmdef_file.pl` for each consecutive pair of PrgI protomers in the

482 direction from base to tip<sup>7,8,24,50</sup>. Measurements were limited to 26 protomers and started from  
483 PrgI<sub>12</sub> in the substrate-trapped filament. UCSF Chimera and ChimeraX were used for molecular  
484 visualization<sup>39,42</sup>.

## 485 **References**

- 486 1. Hueck, C. J. Type III protein secretion systems in bacterial pathogens of animals and plants.  
487 *Microbiol. Mol. Biol. Rev. MMBR* **62**, 379–433 (1998).
- 488 2. Galán, J. E. & Waksman, G. Protein-injection machines in bacteria. *Cell* **172**, 1306–1318 (2018).
- 489 3. Stebbins, C. E. & Galán, J. E. Maintenance of an unfolded polypeptide by a cognate chaperone in  
490 bacterial type III secretion. *Nature* **414**, 77–81 (2001).
- 491 4. Lara-Tejero, M., Kato, J., Wagner, S., Liu, X. & Galán, J. E. A sorting platform determines the order  
492 of protein secretion in bacterial type III systems. *Science* **331**, 1188–1191 (2011).
- 493 5. Schraidt *et al.* Topology and organization of the *Salmonella* typhimurium type III secretion needle  
494 complex components. *PLoS Pathog.* **6**, e1000824 (2010).
- 495 6. Hu, J. *et al.* T3S injectisome needle complex structures in four distinct states reveal the basis of  
496 membrane coupling and assembly. *Nat. Microbiol.* 2010–2019 (2019) doi:10.1038/s41564-019-0545-  
497 z.
- 498 7. Loquet, A., Sgourakis, N. G., Gupta, R. & Giller, K. Atomic model of the type III secretion system  
499 needle. *Nature* **486**, 276–279 (2012).
- 500 8. Hu, J. *et al.* Cryo-EM analysis of the T3S injectisome reveals the structure of the needle and open  
501 secretin. *Nat. Commun.* **9**, 3840–3840 (2018).
- 502 9. Park, D. *et al.* Visualization of the type III secretion mediated *Salmonella*–host cell interface using  
503 cryo-electron tomography. *eLife* **7**, e39514 (2018).
- 504 10. Kubori, T. *et al.* Supramolecular structure of the *Salmonella* typhimurium type III protein secretion  
505 system. *Science* **280**, 602–605 (1998).
- 506 11. Marlovits, T. C. *et al.* Structural insights into the assembly of the type III secretion needle complex.

- 507 *Science* **306**, 1040–1042 (2004).
- 508 12. Johnson, S., Kuhlen, L., Deme, J. C., Abrusci, P. & Lea, S. M. The structure of an injectisome export  
509 gate demonstrates conservation of architecture in the core export gate between flagellar and virulence  
510 type III secretion systems. *mBio* **10**, e00818-19 (2019).
- 511 13. Kuhlen, L. *et al.* The substrate specificity switch FlhB assembles onto the export gate to regulate type  
512 three secretion. *Nat. Commun.* **11**, 1–10 (2020).
- 513 14. Lunelli, M. *et al.* Cryo-EM structure of the *Shigella* type III needle complex. *PLoS Pathog.* **16**,  
514 e1008263 (2020).
- 515 15. Kuhlen, L. *et al.* Structure of the core of the type III secretion system export apparatus. *Nat. Struct.*  
516 *Mol. Biol.* **25**, 583–590 (2018).
- 517 16. Galán, J. E. & Wolf-Watz, H. Protein delivery into eukaryotic cells by type III secretion machines.  
518 *Nature* **444**, 567–573 (2006).
- 519 17. Schlumberger, M. C. *et al.* Real-time imaging of type III secretion: *Salmonella* SipA injection into  
520 host cells. *PNAS* **102**, 12548–12553 (2005).
- 521 18. Radics, J., Königsmaier, L. & Marlovits, T. C. Structure of a pathogenic type 3 secretion system in  
522 action. *Nat. Struct. Mol. Biol.* **21**, 82–87 (2014).
- 523 19. Dohlich, K., Zumsteg, A. B., Goosmann, C. & Kolbe, M. A substrate-fusion protein is trapped inside  
524 the type III secretion system channel in *Shigella flexneri*. *PLoS Pathog* **10**, e1003881 (2014).
- 525 20. McDermott, J. E. *et al.* Minireview: Computational prediction of type III and IV secreted effectors in  
526 gram-negative bacteria. *Infect. Immun.* **79**, 23–32 (2011).
- 527 21. Buchko, G. W. *et al.* A multi-pronged search for a common structural motif in the secretion signal of  
528 *Salmonella enterica* serovar Typhimurium type III effector proteins. *Mol. Biosyst.* **6**, 2448–2458  
529 (2010).
- 530 22. Kimbrough, T. G. & Miller, S. I. Contribution of *Salmonella* typhimurium type III secretion  
531 components to needle complex formation. *PNAS* **97**, 11008–11013 (2000).
- 532 23. Ward, E. *et al.* Type-III secretion pore formed by flagellar protein FliP. *Mol. Microbiol.* **107**, 94–103

- 533 (2018).
- 534 24. Guo, E. Z. *et al.* A polymorphic helix of a *Salmonella* needle protein relays signals defining distinct  
535 steps in type III secretion. *PLOS Biol.* **17**, e3000351 (2019).
- 536 25. Basler, M., Pilhofer, M., Henderson, G. P., Jensen, G. J. & Mekalanos, J. J. Type VI secretion  
537 requires a dynamic contractile phage tail-like structure. *Nature* **483**, 182–186 (2012).
- 538 26. Diepold, A. *et al.* A dynamic and adaptive network of cytosolic interactions governs protein export  
539 by the T3SS injectisome. *Nat. Commun.* **8**, 15940 (2017).
- 540 27. Hu, B., Lara-Tejero, M., Kong, Q., Galán, J. E. & Liu, J. *In situ* molecular architecture of the  
541 *Salmonella* Type III secretion machine. *Cell* **168**, 1065–1074 (2017).
- 542 28. Chabloz, A. *et al.* Salmonella-based platform for efficient delivery of functional binding proteins to  
543 the cytosol. *Commun. Biol.* **3**, 1–11 (2020).
- 544 29. Widmaier, D. M. *et al.* Engineering the *Salmonella* type III secretion system to export spider silk  
545 monomers. *Mol. Syst. Biol.* **5**, 309 (2009).
- 546 30. Rüssmann, H. *et al.* Delivery of epitopes by the *Salmonella* type III secretion system for vaccine  
547 development. *Science* **281**, 565–568 (1998).
- 548 31. Paul, K., Erhardt, M., Hirano, T., Blair, D. F. & Hughes, K. T. Energy source of flagellar type III  
549 secretion. *Nature* **451**, 489–492 (2008).
- 550 32. Zivanov, J., Nakane, T. & Scheres, S. H. W. Estimation of high-order aberrations and anisotropic  
551 magnification from cryo-EM data sets in RELION-3.1. *IUCrJ* **7**, 253–267 (2020).
- 552 33. Zivanov, J. *et al.* New tools for automated high-resolution cryo-EM structure determination in  
553 RELION-3. *eLife* **7**, e42166 (2018).
- 554 34. Zheng, S. Q. *et al.* MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-  
555 electron microscopy. *Nat. Methods* **14**, 331–332 (2017).
- 556 35. Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron  
557 micrographs. *J. Struct. Biol.* **192**, 216–221 (2015).
- 558 36. Wagner, T. *et al.* SPHIRE-crYOLO is a fast and accurate fully automated particle picker for cryo-




- 559 EM. *Commun. Biol.* **2**, 1–13 (2019).
- 560 37. Bordoli, L. *et al.* Protein structure homology modeling using SWISS-MODEL workspace. *Nat.*  
561 *Protoc.* **4**, 1–13 (2009).
- 562 38. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N. & Sternberg, M. J. E. The Phyre2 web portal  
563 for protein modeling, prediction and analysis. *Nat. Protoc.* **10**, 845–858 (2015).
- 564 39. Pettersen, E. F. *et al.* UCSF Chimera - a visualization system for exploratory research and analysis. *J.*  
565 *Comput. Chem.* **25**, 1605–1612 (2004).
- 566 40. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. *Acta*  
567 *Crystallogr. D Biol. Crystallogr.* **66**, 486–501 (2010).
- 568 41. Croll, T. I. ISOLDE: A physically realistic environment for model building into low-resolution  
569 electron-density maps. *Acta Crystallogr. Sect. Struct. Biol.* **74**, 519–530 (2018).
- 570 42. Goddard, T. D. *et al.* UCSF ChimeraX: meeting modern challenges in visualization and analysis.  
571 *Protein Sci.* **27**, 14–25 (2018).
- 572 43. Barad, B. A. *et al.* EMRinger: Side-chain-directed model and map validation for 3D Electron  
573 Cryomicroscopy. *Nat. Methods* **12**, 943–946 (2015).
- 574 44. Williams, C. J. *et al.* MolProbity: More and better reference data for improved all-atom structure  
575 validation. *Protein Sci. Publ. Protein Soc.* **27**, 293–315 (2018).
- 576 45. Liebschner, D. *et al.* Macromolecular structure determination using X-rays, neutrons and electrons:  
577 Recent developments in Phenix. *Acta Crystallogr. Sect. Struct. Biol.* **75**, 861–877 (2019).
- 578 46. Lang, P. T. *et al.* Automated electron-density sampling reveals widespread conformational  
579 polymorphism in proteins. *Protein Sci. Publ. Protein Soc.* **19**, 1420–1431 (2010).
- 580 47. Spreter, T. *et al.* A conserved structural motif mediates formation of the periplasmic rings in the type  
581 III secretion system. *Nat. Struct. Mol. Biol.* **16**, 468–476 (2009).
- 582 48. Bergeron, J. R. C. *et al.* A Refined Model of the Prototypical *Salmonella* SPI-1 T3SS Basal Body  
583 Reveals the Molecular Basis for Its Assembly. *PLOS Pathog.* **9**, e1003307 (2013).
- 584 49. Smart, O. S., Neduelil, J. G., Wang, X., Wallace, B. A. & Sansom, M. S. P. HOLE: A program for

- 585 the analysis of the pore dimensions of ion channel structural models. *J. Mol. Graph.* **14**, 354–360  
586 (1996).
- 587 50. DiMaio, F., Leaver-Fay, A., Bradley, P., Baker, D. & André, I. Modeling symmetric macromolecular  
588 structures in Rosetta3. *PLoS ONE* **6**, e20450 (2011).
- 589 51. Kucukelbir, A., Sigworth, F. J. & Tagare, H. D. Quantifying the local resolution of cryo-EM density  
590 maps. *Nat. Methods* **11**, 63–65 (2014).
- 591 52. Pintilie, G. & Chiu, W. Comparison of Segger and other methods for segmentation and rigid-body  
592 docking of molecular components in cryo-EM density maps. *Biopolymers* **97**, 742–760 (2012).
- 593 53. Pintilie, G., Zhang, J., Chiu, W. & Gossard, D. Identifying components in 3D density maps of protein  
594 nanomachines by multi-scale segmentation. *IEEE/NIH Life Sci. Syst. Appl. Workshop IEEE/NIH Life*  
595 *Sci. Syst. Appl. Workshop* **2009**, 44–47 (2009).
- 596 54. Madeira, F. *et al.* The EMBL-EBI search and sequence analysis tools APIs in 2019. *Nucleic Acids*  
597 *Res.* **47**, W636–W641 (2019).
- 598 55. Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server.  
599 *Nucleic Acids Res.* **42**, W320–W324 (2014).
- 600 56. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. *J. Mol.*  
601 *Biol.* **372**, 774–797 (2007).

602 **Acknowledgements:** We thank all members of the Marlovits Laboratory including Catalin  
603 Bunduc, Biao Yuan, and Barbara Grueter, for their support of this project. We would like to thank  
604 Wolfgang Lugmayr and Frank DiMaio for their help with StarMap, Rosetta, and the filament  
605 analysis. We would also like to thank Tristan Croll for his significant support with ISOLDE. High-  
606 performance computing was possible through access to the HPC at DESY/Hamburg (Germany)  
607 and the Vienna Scientific Cluster (Austria). Part of this work was performed at the CryoEM  
608 Facility at CSSB, supported by the UHH and DFG grant numbers (INST152/772-1 | 152/774-1 |  
609 152/775-1 | 152/776-1 | 152/777-1 FUGG). **Funding:** This project was supported by funds

610 available to TCM through the Behörde für Wissenschaft, Forschung und Gleichstellung of the city  
611 of Hamburg at the Institute of Structural and Systems Biology at the University Medical Center  
612 Hamburg-Eppendorf, the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy  
613 of Sciences, and the Research Institute of Molecular Pathology (IMP). TCM (and SM) received  
614 funding through grant I 2408-B22 furnished by the Austrian Science Fund (FWF). DF was funded  
615 by a DFG research fellowship return grant (FA1518/2-1). VK was supported by Boehringer  
616 Ingelheim Fonds PhD fellowship. **Author contributions:** SM, DF designed experiments. SM, DF  
617 generated constructs. NGM and MP generated knockout strains. SM, VK, OV purified complexes.  
618 SM, DF performed biochemical assays. SM, JW vitrified samples and collected cryoEM images.  
619 SM collected negative stain images. SM, DF, NGM built the atomic model. SM DF, NGM, TCM  
620 interpreted data. TCM processed cryoEM data. SM, DF, TCM wrote and revised the paper. All  
621 authors read, corrected and approved the manuscript. TCM conceived the study and supervised the  
622 project. **Competing Interests:** Authors declare no competing interests. **Data and materials**  
623 **availability:** maps have been deposited at the EMDB database. Models have been deposited at the  
624 PDB.

625 **Figures**



627 **Fig. 1. CryoEM map of the *S. enterica* sv. Typhimurium needle complex engaged with the**  
628 **effector protein substrate SptP3x-GFP. a,** The non-symmetrized cryoEM (C1) reconstruction  
629 of the substrate-engaged needle complex (left) with a vertical cross section through the center  
630 (right) revealing the substrate shown in magenta throughout the translocation channel. Upper left,  
631 is a cartoon schematic of the needle complex injectisome in the bacterial inner and outer  
632 membranes (IM/OM) and in contact with a host cell membrane (HCM). NC: needle complex, SP:  
633 sorting platform, OR: outer rings, IR: inner rings. PrgH<sub>1-24</sub>: dark purple, PrgK<sub>1-24</sub>: amaranth, InvG<sub>1-</sub>  
634 <sub>15/16</sub>: dark green, SpaQ<sub>1-4</sub>: yellow colors, SpaP<sub>1-5</sub>: blue colors, SpaR: orange, PrgJ<sub>1-6</sub>: red, PrgI<sub>1-72</sub>:  
635 salmon. **b,** Top and bottom views of the C1 map showing the export apparatus (EA) and substrate.  
636 **c,** CryoEM map of the filament, inner rod and the export apparatus components. SpaP<sub>1</sub> has been  
637 removed to aid visualization of the substrate.

638



639

640

641

642






644 **Fig. 2. The export apparatus (EA) forms a translocation channel for substrates.** **a**, Modular  
645 assembly of the substrate-trapped EA, inner rod (PrgJ) and the first six PrgI subunits of the helical  
646 filament. Individual protein components are shown in the dashed box below. SptP3x-GFP is shown  
647 in magenta. **b**, Left: view of the EA with SpaP<sub>1</sub>, PrgJ<sub>1-2</sub> and PrgI<sub>1</sub> removed and the substrate  
648 translocation path displayed as a white surface. Right: four discrete sections (portal, channel,  
649 atrium and tunnel) of the translocation path are shown with the EM density corresponding to the  
650 substrate (threshold: 0.015). Right box: magnification highlighting surfaces of residues forming  
651 hydrophilic and hydrophobic staircases encircling the portal and channel. Green: hydrophilic;  
652 white: neutral; gold: hydrophobic.

653

654

655

656



657

658 **Fig. 3. The Q1-belt portal of the EA facilitates substrate loading into the needle complex. a,**

659 Surface representation of the substrate-engaged EA, with SpaQ<sub>1-4</sub> shown as yellow ribbon

660 diagrams. Right box: a magnified view of the conserved SpaQ glutamine residues Gln41, Gln43

661 and Gln45 involved in substrate engagement, depicted in stick representation. **b,** Hydrogen-bond

662 formation between the substrate backbone and SpaQ<sub>3</sub> Gln43 and SpaQ<sub>4</sub> Gln43. The surfaces

663 represent EM density (threshold: 0.014). **c,** Side view of the SpaQ Q1-belt displayed as ribbon


664 diagrams encircling the SptP3x-GFP substrate with the side chains of Gln41/43/45 shown in stick

665 representation. Far right: Surface representations of the Q1 belt residues Gln41/43/45 colored by

666 hydrophobicity. Green: hydrophilic; white: neutral; gold: hydrophobic.

667





669 **Fig. 4. Opening of the M-gate in the EA facilitates substrate translocation and is crucial for**  
670 **needle complex assembly and cellular fitness. a**, Bottom and top views of the EA, with M-gate  
671 shown in the lower panels, depicted in surface representation in a closed or open (substrate  
672 engaged) state. Methionine residues 186/7 are displayed in yellow and Phe212 in green. SpaR is  
673 displayed transparent in the top views. **b**, Left: surface representations of the M-gate residues  
674 Met186/7 colored by hydrophobicity. Middle and right: side and bottom views of the M-gate  
675 staircase with Met186/7 and Phe212 depicted in stick representation. **c**, Quantification of needle  
676 complexes (n=20 cells) in *Salmonella* SpaP knockout strains complemented with SpaP WT (WT  
677 CP) or with mutants targeting the conserved 185-Met-Met-Met-187 motif of the M-gate (GGG-  
678 WWW). Boxplot whiskers show min and max counts. Individual counts are represented by dots.  
679 Needle complexes were counted by three individuals and averaged. **d**, Optical densities of the  
680 *Salmonella* strains in (c). Plotted is the mean difference in OD<sub>600</sub> between cultures grown for 6 hrs  
681 under T3SS-inducing and non-inducing conditions. Error bars represent SD and asterisks represent  
682 a significant difference compared to WT CP (GGG  $P < 0.0001$ , AAA  $P < 0.0001$ , CCC  $P = 0.002$ ).  
683 A one-way ANOVA and a Dunnett's test were used to assess statistical significance between the  
684 WT control (WT CP) and M-gate substitution strains.


685

686

687

688

689




690

691


692 **Fig. 5. Conserved glutamines in SpaP and the SpaR lid together orchestrate substrate**  
693 **transport through the Q2-belt of the EA. a,** Surface representations of the EA showing the SpaR  
694 loop/lid and surrounding Q2 belt. Q2 belt residues are shown in light green, M-gate residues in  
695 yellow. Numbers correspond to residues building the SpaR lid. The M-gate, Phe212 and Ile114  
696 are displayed in yellow, dark green and red, respectively. **b,** Left: surface representations of the  
697 Q2 belt residues Gln44/45 colored by hydrophobicity. Right: close up of Q2 belt with Gln44/45  
698 displayed in stick representation and SpaPs as ribbon diagrams. **c,** Hydrogen-bond formation  
699 between the substrate backbone and SpaP<sub>2</sub> Gln45. The surfaces represent EM density (threshold:  
700 0.016).





701  
 702 **Fig. 6. Density in the lipid-stabilized atrium and the filament tunnel suggests possible**  
 703 **transport of partially folded substrates.** **a**, Top views of EM densities corresponding to lipids  
 704 (yellow, L1-L5) residing in a circular gap formed by SpaP and SpaR proteins in the EA. The lipids

705 stabilize PrgJ  $\alpha$ -helices  $\alpha$ -1 and  $\alpha$ -2 forming the PrgJ forks (right boxes; PrgJs displayed as red  
706 ribbon diagrams). **b**, Size constraints of the substrate translocation path through the needle  
707 complex. M-gate ( $\varnothing \sim 5.5\text{\AA}$ ), Q2-belt ( $\varnothing \sim 6\text{\AA}$ , state 1;  $\sim 10\text{\AA}$ , state 2), atrium ( $\varnothing \sim 13.5\text{\AA}$ ), tunnel ( $\varnothing$   
708  $\sim 13\text{\AA}$ ). **c**, Top: example  $\alpha$ -helices and surface diameter calculations of poly-Gly, poly-Ala and  
709 poly-Val  $\alpha$ -helices. Middle: vertical cross sections through the filament tunnel with density  
710 corresponding to the SptP3x-GFP substrate shown at increasing map thresholds. Bottom:  
711 secondary structure elements illustrate that the substrate EM density at high thresholds is  
712 sufficiently bulky to accommodate  $\alpha$ -helices.



713

714 **Fig. 7. Model for substrate translocation through the EA of T3SSs.** Disordered N-termini of  
715 effector proteins (magenta circles) enter the Q1-belt (blue circles) of the EA facing the bacterial  
716 cytoplasm. Successive binding of the substrate backbone to conserved glutamines facilitates  
717 penetration through the Q1-belt and loading of the substrate into the needle complex, a process  
718 putatively fueled by the concerted action of the ATPase (InvC) and the proton motive force (PMF).  
719 The substrate then penetrates the M-gate. Disruption of its hydrophobic interface (Met186-  
720 Met187; yellow ovals; SpaR Phe212; green hexagon) expands the gate and causes the SpaR loop

721 (orange ratchet) to flip into a vertical position together generating a narrow path for the  
722 translocation of the unfolded substrate chain. The substrate then proceeds up to the Q2-belt (green  
723 circles) and SpaR Ile114 (black pawl) which together stabilize the substrate above the M-gate and  
724 the loop likely acts as a linear ratchet to engage and steer substrates further towards the atrium and  
725 filament, ultimately facilitating effector protein secretion.

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743